A cancer patient gets a new lease on life
Posts
Novartis News Empowering the next generation of healthcare leaders
Novartis News Empowering the next generation of healthcare leaders
Novartis News Giving voice to people with a misunderstood disease
Novartis News Giving voice to people with a misunderstood disease
Novartis News Water project revives rural community in India
Novartis News Water project revives rural community in India
Novartis News A partnership against epilepsy
Novartis News A partnership against epilepsy
Novartis News Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors
Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors
arcticnovartis
- In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs.
Follow us on Facebook
ADDRESS – ZIMBABWE
Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe
ADDRESS – ZAMBIA
Plot 43504
Apex Chalala
Off Kasama Road
Lusaka Zambia